Literature DB >> 6151210

Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.

F Müller-Spahn, M Ackenheil, M Albus, G May, D Naber, D Welter, K Zander.   

Abstract

The sensitivity of the dopaminergic hypothalamic pituitary system, as indicated by growth hormone (GH) release after apomorphine (0.5 mg SC), was studied in 11 chronic schizophrenic in-patients under long-term neuroleptic (NL) therapy and after 12 and 30 days' drug withdrawal. GH peak levels after a 12-day drug-free period were significantly elevated (13.1 +/- 12 ng/ml) as compared to NL therapy (4.6 +/- 6.1 ng/ml). Controls showed a significant higher mean peak GH response (13.6 +/- 10 ng/ml) compared to chronic schizophrenic patients under long-term NL therapy. The GH response of patients with symptoms of tardive dyskinesia (TD) did not differ significantly from that of patients without signs of TD. The prolactin (PRL) serum levels under long-term NL treatment were within the normal range in male schizophrenics but decreased significantly after 12 days' drug withdrawal. The data presented indicate a reduced sensitivity of the hypothalamic-pituitary dopamine receptors under long-term NL therapy. The significant increase in GH response on day 12 probably corresponds to a readjustment from a mostly blunted GH response under NL therapy back to stimulated levels of normal controls. No supersensitivity of the pituitary dopamine receptors could be detected.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151210     DOI: 10.1007/BF00555228

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  Apomorphine: effect on growth hormone.

Authors:  I Maany; A Frazer; J Mendels
Journal:  J Clin Endocrinol Metab       Date:  1975-01       Impact factor: 5.958

2.  Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.

Authors:  S Lal; J B Martin; C E De la Vega; H G Friesen
Journal:  Clin Endocrinol (Oxf)       Date:  1975-05       Impact factor: 3.478

3.  Long-term changes in the sensitivity of pre-and postsynaptic dopamine receptors in mouse striatum evidenced by behavioural and biochemical studies.

Authors:  M P Martres; J Costentin; M Baudry; H Marcais; P Protais; J C Schwartz
Journal:  Brain Res       Date:  1977-11-11       Impact factor: 3.252

4.  A neuroendocrine study of supersensitivity in tardive dyskinesia.

Authors:  C A Tamminga; R C Smith; G Pandey; L A Frohman; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1977-10

5.  Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment.

Authors:  T Kolakowska; D H Wiles; M G Gelder; A S McNeilly
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

6.  Prolactin responses to neuroleptics in normal and schizophrenic subjects.

Authors:  P H Gruen; E J Sachar; G Langer; N Altman; M Leifer; A Frantz; F S Halpern
Journal:  Arch Gen Psychiatry       Date:  1978-01

Review 7.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

Review 8.  Tardive dyskinesia.

Authors:  J Gerlach
Journal:  Dan Med Bull       Date:  1979-08

9.  A radioimmunoassay for human prolactin.

Authors:  P Hwang; H Guyda; H Friesen
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

10.  Postsynaptic supersensitivity in schizophrenia.

Authors:  G N Pandey; D L Garver; C Tamminga; S Ericksen; S I Ali; J M Davis
Journal:  Am J Psychiatry       Date:  1977-05       Impact factor: 18.112

View more
  1 in total

1.  Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology.

Authors:  F Müller-Spahn; M Ackenheil; M Albus; C Botschev; D Naber; D Welter
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.